RIGEL PHARMACEUTICALS, INC. Proceeds from Common Stock Issued
RIGEL PHARMACEUTICALS, INC. (RIGL) reported Proceeds from Common Stock Issued of $67.16 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-03-02.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2021-03-02
- RIGEL PHARMACEUTICALS, INC. proceeds from issuance of common stock for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- RIGEL PHARMACEUTICALS, INC. proceeds from issuance of common stock for the quarter ending 2018-09-30 was $0.00, a 100.00% decline year-over-year.
- RIGEL PHARMACEUTICALS, INC. proceeds from issuance of common stock for the quarter ending 2017-12-31 was $65.44M, a 4679.99% increase year-over-year.
- RIGEL PHARMACEUTICALS, INC. proceeds from issuance of common stock for the quarter ending 2017-09-30 was $2.57M, a 80.05% decline year-over-year.
- RIGEL PHARMACEUTICALS, INC. proceeds from issuance of common stock for fiscal 2018 was $67.16M, a 41.18% decline from fiscal 2017.
- RIGEL PHARMACEUTICALS, INC. proceeds from issuance of common stock for fiscal 2017 was $114.18M, a 384.10% increase from fiscal 2016.
- RIGEL PHARMACEUTICALS, INC. proceeds from issuance of common stock for fiscal 2016 was $23.59M, a 345.69% increase from fiscal 2015.
- RIGEL PHARMACEUTICALS, INC. proceeds from issuance of common stock for fiscal 2015 was $5.29M, a 352.31% increase from fiscal 2014.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month | Proceeds from Issuance of Common Stock 17 month |
|---|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | $0.00 derived: sum of 2 quarters · filed 2021-03-02 | $67.16M 10-K · filed 2021-03-02 | ||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $67.16M 10-Q · filed 2019-11-05 | |||
| 2018-06-30 | $67.16M 10-Q · filed 2019-08-06 | ||||
| 2017-12-31 | $65.44M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $68.00M derived: sum of 2 quarters · filed 2020-02-27 | $71.10M derived: sum of 3 quarters · filed 2020-02-27 | $114.18M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $2.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $5.66M derived: sum of 2 quarters · filed 2018-11-06 | $48.74M 10-Q · filed 2018-11-06 | $50.11M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-06-30 | $3.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $46.17M 10-Q · filed 2018-08-08 | $47.54M derived: sum of 3 quarters · filed 2019-02-28 | $60.41M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-03-31 | $43.08M 10-Q · filed 2018-05-01 | $44.45M derived: sum of 2 quarters · filed 2019-02-28 | $57.32M derived: sum of 3 quarters · filed 2019-02-28 | ||
| 2016-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $14.24M derived: sum of 2 quarters · filed 2019-02-28 | $23.59M 10-K · filed 2019-02-28 | $30.00M 10-K · filed 2017-03-07 | |
| 2016-09-30 | $12.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $22.22M 10-Q · filed 2017-11-07 | |||
| 2016-06-30 | $9.35M 10-Q · filed 2017-08-01 | ||||
| 2015-12-31 | $4.17M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $4.26M derived: sum of 2 quarters · filed 2018-03-06 | $5.28M derived: sum of 3 quarters · filed 2018-03-06 | $5.29M 10-K · filed 2018-03-06 | |
| 2015-09-30 | $98.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-03 | $1.11M derived: sum of 2 quarters · filed 2015-11-03 | $1.13M 10-Q · filed 2015-11-03 | $1.61M derived: sum of 4 quarters · filed 2015-11-03 | |
| 2015-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $1.03M 10-Q · filed 2015-08-04 | $1.51M derived: sum of 3 quarters · filed 2015-08-04 | $1.51M derived: sum of 4 quarters · filed 2015-11-03 | |
| 2015-03-31 | $17.00K 10-Q · filed 2015-05-07 | $497.00K derived: sum of 2 quarters · filed 2015-05-07 | $502.00K derived: sum of 3 quarters · filed 2015-11-03 | $1.16M derived: sum of 4 quarters · filed 2015-11-03 | |
| 2014-12-31 | $480.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03 | $485.00K derived: sum of 2 quarters · filed 2015-11-03 | $1.15M derived: sum of 3 quarters · filed 2015-11-03 | $1.17M 10-K · filed 2015-03-03 | |
| 2014-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-03 | $666.00K derived: sum of 2 quarters · filed 2015-11-03 | $690.00K 10-Q · filed 2015-11-03 | $919.00K derived: sum of 4 quarters · filed 2015-11-03 | |
| 2014-06-30 | $661.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $685.00K 10-Q · filed 2015-08-04 | $914.00K derived: sum of 3 quarters · filed 2015-08-04 | $914.00K derived: sum of 4 quarters · filed 2015-08-04 | |
| 2014-03-31 | $24.00K 10-Q · filed 2015-05-07 | $253.00K derived: sum of 2 quarters · filed 2015-05-07 | $253.00K derived: sum of 3 quarters · filed 2015-05-07 | ||
| 2013-12-31 | $229.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03 | $229.00K derived: sum of 2 quarters · filed 2015-03-03 | $1.05M 10-K · filed 2015-03-03 | ||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $822.00K 10-Q · filed 2014-11-04 | |||
| 2013-06-30 | $822.00K 10-Q · filed 2014-08-05 | ||||
| 2012-12-31 | $136.53M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03 | $137.72M derived: sum of 2 quarters · filed 2015-03-03 | $138.61M derived: sum of 3 quarters · filed 2015-03-03 | $139.09M 10-K · filed 2015-03-03 | |
| 2012-09-30 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | $2.08M derived: sum of 2 quarters · filed 2013-11-05 | $2.57M 10-Q · filed 2013-11-05 | $3.47M derived: sum of 4 quarters · filed 2014-03-04 | |
| 2012-06-30 | $885.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $1.37M 10-Q · filed 2013-08-06 | $2.28M derived: sum of 3 quarters · filed 2014-03-04 | $2.48M derived: sum of 4 quarters · filed 2014-03-04 | |
| 2012-03-31 | $488.00K 10-Q · filed 2013-05-07 | $1.39M derived: sum of 2 quarters · filed 2014-03-04 | $1.59M derived: sum of 3 quarters · filed 2014-03-04 | $143.22M derived: sum of 4 quarters · filed 2014-03-04 | |
| 2011-12-31 | $903.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-04 | $1.10M derived: sum of 2 quarters · filed 2014-03-04 | $142.73M derived: sum of 3 quarters · filed 2014-03-04 | $142.78M 10-K · filed 2014-03-04 | |
| 2011-09-30 | $202.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $141.82M derived: sum of 2 quarters · filed 2012-11-06 | $141.88M 10-Q · filed 2012-11-06 | $142.65M derived: sum of 4 quarters · filed 2013-03-05 | |
| 2011-06-30 | $141.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $141.67M 10-Q · filed 2012-08-07 | $142.44M derived: sum of 3 quarters · filed 2013-03-05 | $142.68M derived: sum of 4 quarters · filed 2013-03-05 | |
| 2011-03-31 | $52.00K 10-Q · filed 2012-05-01 | $823.00K derived: sum of 2 quarters · filed 2013-03-05 | $1.06M derived: sum of 3 quarters · filed 2013-03-05 | ||
| 2010-12-31 | $771.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-05 | $1.01M derived: sum of 2 quarters · filed 2013-03-05 | $1.96M 10-K · filed 2013-03-05 | ||
| 2010-09-30 | $235.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-01 | $1.19M 10-Q · filed 2011-11-01 | |||
| 2010-06-30 | $958.00K 10-Q · filed 2011-08-02 | ||||
| 2009-12-31 | $103.60M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |